Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

16 juin 2016 08h00 HE | Source: Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics Announces Positive Phase IV Results of Silenor® vs. Zolpidem Head-to-Head Arousability Study

Data demonstrated that Pernix Therapeutics’ Silenor® 6 mg was superior to zolpidem 10 mg on all measures evaluated. Study results presented at SLEEP 2016 international meeting MORRISTOWN, N.J.,...
25 mai 2016 08h00 HE | Source: Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics Announces the Issuance of Three New Orange Book Patents for Zohydro® ER with BeadTek™

MORRISTOWN, N.J., May 25, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that the United States Patent and Trademark...
11 mai 2016 08h00 HE | Source: Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics Announces CEO Transition

MORRISTOWN, N.J., May 11, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that Doug Drysdale, after discussions with...